Paloma Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Jamaica Plain MA United States (2005)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2010
NCT01033721
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Palobiofarma SL

Active Ingredients

Drugs in Phase 2 Trials (4)

pbf-509 (1 trial)

pbf-677 (2 trials)

pbf-680 (3 trials)

spartalizumab (1 trial)

Drugs in Phase 1 Trials (4)

palomid 529 (1 trial)

pbf-1129 (1 trial)

pbf-1650 (1 trial)

pbf-999 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Glaucoma (Phase 1)

Huntington Disease (Phase 1)

Lung Neoplasms (Phase 2)

Macular Degeneration (Phase 1)

Psoriasis (Phase 1)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 8